Verastem to present RAMP 201 analyses at IGCS 2026
Verastem Oncology said new RAMP 201 molecular profiling and external control arm analyses on avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.
Verastem Oncology said new RAMP 201 molecular profiling and external control arm analyses on avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.